

Daily Research Report



Dt.: 3 Aug, 2026

INDEX	NIFTY	BANKNIFTY	USDINR
Outlook	Bullish	Bullish	Bearish

INSTITUTIONAL TRADING ACTIVITY IN CRS.			
Category	Buy Value	Sell Value	Net Value
FII	19045.51	18768.03	+277.48
DII	19885.80	18768.03	+2260.37

TRADE STATISTICS FOR 31/07/2026			
Instrument	No. of Contracts	Turnover (Cr.)	Put Call Ratio
Index Fut.	57273	9349.42	
Stock Fut.	1164138	80333.05	
Index Opt.	85300773	13520069	1.14
Stock Opt.	6480750	457856.5	
F&O Total	93002934	14067608	



PIVOT TABLE					
	R2	R1	PIVOT	S1	S2
NIFTY	24522	24469	24370	24312	24244
BANKNIFTY	57543	57404	57271	57132	57000

NIFTY FUT.			
	TRIGGER	T1	T2
Above	24400	24646	24788
Below	23600	23462	23348

BANK NIFTY FUT.			
	TRIGGER	T1	T2
Above	58000	59050	59672
Below	56000	55254	54678



Nifty concluded the week on a strong note, sustaining above its 5 DEMA and 5 WEMA, reflecting improving near-term strength. The index is now approaching the crucial 24420 breakout zone, while the 23800–24000 region has emerged as a strong near-term base and 24400 remains the key resistance. Momentum indicators have turned constructive, with both daily and weekly RSI holding above 50, while the ADX is rebounding from an extreme low, indicating the potential for a fresh directional momentum phase. A sustained move above 24250 would reinforce the recovery and increase the probability of a decisive breakout above 24420, potentially opening the way towards 25000. On the downside, a slippage below 24100 could expose Nifty to the 23700 trendline support, which now serves as the key near-term stop-loss zone. Traders should continue focusing on stock-specific opportunities and consider fresh longs on a sustained move above 24250–24420. Investors may continue staggered accumulation of fundamentally strong stocks, while deploying fresh capital more aggressively following a confirmed breakout above 24420.

Trade Scanner: **ABCAPITAL, AUROPHARMA, CGPOWER, CROMPTON, ICICIBANK, JIOFIN, MUTHOOTFIN, NATIONALUM, TATASTEEL, TIINDIA, UNOMINDA, ADANIENT, COLPAL, GODREJCP, HDFCBANK, ITC, LUPIN, MANKIND, MAXHEALTH, MFSL, SHREECEM, VBL.**

RESEARCH DESK: Sacchitanand Uttekar - VP - Research (Derivatives & Technicals)

Disclaimer: Investments in securities market are subject to market risk, read all the related documents carefully before investing. The securities quoted are for illustration only and are not recommendatory | Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. **Disclaimer:** This document is for private circulation and information purpose only and should not be regarded as an investment, trading, taxation? legal or price? risk management advice. In no circumstances it is considered as an offer to sale or a solicitation of any offer to buy or sell the Equity derivatives mentioned herein. We and our affiliates, group? companies, directors and employees, and directors and employees of our affiliates and group? companies, including persons involved in the preparation or issuance of this material may (a) have positions in Equity (derivatives or physical) mentioned hereby or (b) have other positions which might have conflicting interest with respect to any related information. The information contained hereby may have been taken from sources which we believe are reliable. We do not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinion expressed reflects judgments at this date and are subject to change without notice. Risk of loss in Equity derivatives trading can be substantial. Persons trading in Equity Derivatives should consider the suitability of trading based upon their resources, risk appetite and other relevant information; and understand that statements regarding future prospects may not be realized.